CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma

CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma

Abstract Polybromo 1 (PBRM1) inactivating mutations are associated with clinical benefit from immune checkpoint inhibitor treatments in clear cell renal cell carcinoma (ccRCC). However, whether targeting PBRM1 has the potential to enhance immunotherapy efficacy in patients with wild‐type PBRM1 and t...

Full description

Saved in:
Bibliographic Details
Main Authors: Yizeng Fan, Weichao Dan, Taotao Que, Yi Wei, Bo Liu, Zixi Wang, Yulin Zhang, Yuzhao Wang, Tianjie Liu, Yanxin Zhuang, Mengxing Li, Chendong Guo, Jin Zeng, Bohan Ma, Lei Li
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Advanced Science
Subjects:
CDC20
Immunotherapy
p62
PBRM1
RCC
Online Access:https://doi.org/10.1002/advs.202412967
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items